06 Jul 2012, BioSpectrum Bureau , BioSpectrum
Singapore: Amgen completed the acquisition of KAI Pharmaceuticals, a privately held company based in South San Francisco. The acquisition was initially announced April 10, 2012 and includes KAI's lead product candidate KAI-4169.
The candidate is is a novel agent that was being initially studied for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease, who are on dialysis. KAI has previously reported compelling phase IIa clinical results for KAI-4169 in this indication. KAI-4169 is administered intravenously at the same time the patient is undergoing dialysis.
The acquisition of KAI Pharmaceuticals follows close on the heels of Amgen's acquisition of Turkey-based MN Pharma.